FindTrial
Sign In

TO STUDY THE NATURE OF DISEASE(SYSTEMIC LUPUS ERYTHEMATOSUS)AND ALSO ROLE OF BIOCHEMICAL MARKER( SERUM ADENOSINE DEAMINASE LEVELS) IN RELATION TO SEVERITY OF DISEASE(SYSTEMIC LUPUS ERYTHEMATOSUS)

STUDY OF CLINICAL PROFILE OF SYSTEMIC LUPUS ERYTHEMATOSUS WITH SPECIAL REFERENCE TO SERUM ADENOSINE DEAMINASE LEVELS AND ITS ASSOCIATION WITH DISEASE ACTIVITY

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/09/028063
Enrollment
55
Registered
2020-09-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M329- Systemic lupus erythematosus, unspecified

Interventions

None listed

Sponsors

UTUKURU NITHIN KUMAR REDDY
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with systemic lupus erythematosus using SLICC criteria.

Exclusion criteria

Exclusion criteria: Active TB and previously diagnosed with TB, and autoimmune diseases like rheumatoid arthritis, psoriasis, systemic sclerosis.

Design outcomes

Primary

MeasureTime frame
To study the association between serum adenosine deaminase levels and disease activity of systemic lupus erythematosus.Timepoint: OCTOBER 2021—

Secondary

MeasureTime frame
1.To study the clinical profile of systemic lupus erythematosus. 2.To compare serum adenosine deaminase levels with other conventional markers like ESR, CRP, ESR/CRP RATIO, C3, C4, ANTI ds dna, and random urine protein creatinine ratio.Timepoint: OCTOBER 2021—

Countries

India

Contacts

Public ContactUTUKURU NITHIN KUMAR REDDY

karturba medical college , manipal,udupi,karnataka.

nithinreddy.u@gmail.com9666517307

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026